1W7G - JenaLib

Asymmetric/Biological Unit

Reformat:	Number of residues per line = ('0' or empty: single-line sequence representation)
	Number of residues per labelling interval =
	UniProt sequence: complete aligned part

Show mapping:	SCOP domains	CATH domains	Pfam domains	Secondary structure (by author)
	SAPs(SNPs)	PROSITE motifs	Exons
	(details for a mapped element are shown in a popup box when the mouse pointer rests over it)

Chain H from PDB  Type:PROTEIN  Length:253
 aligned with THRB_HUMAN | P00734 from UniProtKB/Swiss-Prot  Length:622

    Alignment length:259
                                   373       383       393       403       413       423       433       443       453       463       473       483       493       503       513       523       533       543       553       563       573       583       593       603       613         
          THRB_HUMAN    364 IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE  622
               SCOP domains ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- SCOP domains
               CATH domains 1w7gH01     1w7gH02 H:28-120,H:233-247 Trypsin-like serine proteases                                                 1w7gH01 H:16-27,H:121-232 Tryps      in-like serine proteases                                                                  1w7gH02         CATH domains
               Pfam domains Trypsin-1w7gH01 H:16-238                                                                                                                                                                                                                                  --------- Pfam domains
         Sec.struct. author ....ee........eeeeee....eeeeeeee....eeeehhhh.eehhhhee.hhh.eeeee.............eee.eeeeee..............eeeee................hhhhhhhhh....eeeeee........------......eeeeee..hhhhhhhh........eeee..hhhhh............eeeee......eeeeeeeee..........eeeee...hhhhhhhhhhhhh. Sec.struct. author
                 SAPs(SNPs) ----------------T-----T--------------------------------------C-----H-----------------------------W-----------------------------------------------A----------------------Q--------------------------------------------------------------------V--------------------- SAPs(SNPs)
                PROSITE (1) TRYPSIN_DOM  PDB: H:16-243 UniProt: 364-618                                                                                                                                                                                                                    ---- PROSITE (1)
                PROSITE (2) --------------------------------------TRYPSI----------------------------------------------------------------------------------------------------------------------------------------------------------TRYPSIN_SER ------------------------------------------------- PROSITE (2)
           Transcript 1 (1) -------------Exon 1.10  PDB: H:29-75 UniProt: 377-433                 ---------------------------------------------------------Exon 1.12  PDB: H:129B-184 (gaps) UniProt: 491-552            -----------------------Exon 1.14c  PDB: H:203-247 (gaps)               Transcript 1 (1)
           Transcript 1 (2) Exon 1.9      -------------------------------------------------------Exon 1.11b  PDB: H:75-129B UniProt: 433-491                ------------------------------------------------------------Exon 1.13  PDB: H:184-20----------------------------------------------- Transcript 1 (2)
                1w7g H   16 IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETW------GQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE  247
                                    25        35 |      44        54      |60D|||||   65        75  |     84        94   |   103       113       123      |130       140       | -    |  155       165       175      184A  |||| 190       200    || 208       219  |    228       238         
                                               36A                      60A||||||||               77A                  97A                             129A||                148    150                               184A  ||||               204A|          217|  |                          
                                                                         60B|||||||                                                                     129B|                                                            186A|||                204B           219  |                          
                                                                          60C||||||                                                                      129C                                                             186B||                                 221A                          
                                                                           60D|||||                                                                                                                                        186C|                                                               
                                                                            60E||||                                                                                                                                         186D                                                               
                                                                             60F|||                                                                                                                                                                                                            
                                                                              60G||                                                                                                                                                                                                            
                                                                               60H|                                                                                                                                                                                                            
                                                                                60I

Chain I from PDB  Type:PROTEIN  Length:9
 aligned with HIRV2_HIRME | P09945 from UniProtKB/Swiss-Prot  Length:72

    Alignment length:10
                                    71
         HIRV2_HIRME     62 DFEEIPEEYL   71
               SCOP domains ---------- SCOP domains
               CATH domains ---------- CATH domains
               Pfam domains ---------- Pfam domains
         Sec.struct. author .......-.. Sec.struct. author
                 SAPs(SNPs) ---------- SAPs(SNPs)
                    PROSITE ---------- PROSITE
                 Transcript ---------- Transcript
                1w7g I   55 DFEEIPE-YL   64
                                  | 64
                                 61 | 
                                   63

Chain L from PDB  Type:PROTEIN  Length:27
 aligned with THRB_HUMAN | P00734 from UniProtKB/Swiss-Prot  Length:622

    Alignment length:27
                                   343       353       
          THRB_HUMAN    334 ADCGLRPLFEKKSLEDKTERELLESYI  360
               SCOP domains --------------------------- SCOP domains
               CATH domains --------------------------- CATH domains
               Pfam domains Thrombin_light-1w7gL01      Pfam domains
         Sec.struct. author ........hhhhh....hhhhhhhhh. Sec.struct. author
                 SAPs(SNPs) --------------------------- SAPs(SNPs)
                PROSITE (1) --------------------------- PROSITE (1)
                PROSITE (2) --------------------------- PROSITE (2)
           Transcript 1 (1) 1.------------------------- Transcript 1 (1)
           Transcript 1 (2) -Exon 1.9  PDB: L:1B-15     Transcript 1 (2)
                1w7g L   1A ADCGLRPLFEKKSLEDKTERELLESYI   15
                            ||       8      |14D|||||| 
                           1A|            14A||||||14J 
                            1B             14B|||||||  
                                            14C||||||  
                                             14D|||||  
                                              14E||||  
                                               14F|||  
                                                14G||  
                                                 14H|  
                                                  14I

Legend:		→ Mismatch	(orange background)
	-	→ Gap	(green background, '-', border residues have a numbering label)
		→ Modified Residue	(blue background, lower-case, 'x' indicates undefined single-letter code, labelled with number + name)
	x	→ Chemical Group	(purple background, 'x', labelled with number + name, e.g. ACE or NH2)
	extra numbering lines below/above indicate numbering irregularities and modified residue names etc., number ends below/above '\|'

Classification and Annotation

SCOP Domains (0, 0)

CATH Domains (1, 2)

Pfam Domains (2, 2)

Gene Ontology (56, 57)

Asymmetric/Biological Unit(hide GO term definitions)

Chain H,L (THRB_HUMAN | P00734)

molecular function
	GO:0005509	calcium ion binding	Interacting selectively and non-covalently with calcium ions (Ca2+).
	GO:0008083	growth factor activity	The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.
	GO:0016787	hydrolase activity	Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.
	GO:0008233	peptidase activity	Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
	GO:0005102	receptor binding	Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
	GO:0004252	serine-type endopeptidase activity	Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).
	GO:0008236	serine-type peptidase activity	Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).
	GO:0070053	thrombospondin receptor activity	Combining with thrombospondin and transmitting the signal to initiate a change in cell activity.
biological process
	GO:0006888	ER to Golgi vesicle-mediated transport	The directed movement of substances from the endoplasmic reticulum (ER) to the Golgi, mediated by COP II vesicles. Small COP II coated vesicles form from the ER and then fuse directly with the cis-Golgi. Larger structures are transported along microtubules to the cis-Golgi.
	GO:0006953	acute-phase response	An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals.
	GO:0007596	blood coagulation	The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.
	GO:0007597	blood coagulation, intrinsic pathway	A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.
	GO:0007166	cell surface receptor signaling pathway	A series of molecular signals initiated by activation of a receptor on the surface of a cell. The pathway begins with binding of an extracellular ligand to a cell surface receptor, or for receptors that signal in the absence of a ligand, by ligand-withdrawal or the activity of a constitutively active receptor. The pathway ends with regulation of a downstream cellular process, e.g. transcription.
	GO:0044267	cellular protein metabolic process	The chemical reactions and pathways involving a specific protein, rather than of proteins in general, occurring at the level of an individual cell. Includes cellular protein modification.
	GO:0071260	cellular response to mechanical stimulus	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus.
	GO:0042730	fibrinolysis	A process that solubilizes fibrin in the bloodstream of a multicellular organism, chiefly by the proteolytic action of plasmin.
	GO:0007599	hemostasis	The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.
	GO:0050900	leukocyte migration	The movement of a leukocyte within or between different tissues and organs of the body.
	GO:0007275	multicellular organism development	The biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).
	GO:0048712	negative regulation of astrocyte differentiation	Any process that stops, prevents, or reduces the frequency, rate or extent of astrocyte differentiation.
	GO:0051918	negative regulation of fibrinolysis	Any process that stops, prevents, or reduces the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.
	GO:0010544	negative regulation of platelet activation	Any process that decreases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue.
	GO:0045861	negative regulation of proteolysis	Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.
	GO:0017187	peptidyl-glutamic acid carboxylation	The gamma-carboxylation of peptidyl-glutamic acid; catalyzed by the vitamin K dependent gamma-glutamyl carboxylase.
	GO:0030168	platelet activation	A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
	GO:0030194	positive regulation of blood coagulation	Any process that activates or increases the frequency, rate or extent of blood coagulation.
	GO:0030307	positive regulation of cell growth	Any process that activates or increases the frequency, rate, extent or direction of cell growth.
	GO:0008284	positive regulation of cell proliferation	Any process that activates or increases the rate or extent of cell proliferation.
	GO:0032967	positive regulation of collagen biosynthetic process	Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.
	GO:0014068	positive regulation of phosphatidylinositol 3-kinase signaling	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade.
	GO:1900738	positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway	Any process that activates or increases the frequency, rate or extent of phospholipase C-activating G-protein coupled receptor signaling pathway.
	GO:0001934	positive regulation of protein phosphorylation	Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.
	GO:2000379	positive regulation of reactive oxygen species metabolic process	Any process that activates or increases the frequency, rate or extent of reactive oxygen species metabolic process.
	GO:0051281	positive regulation of release of sequestered calcium ion into cytosol	Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.
	GO:0006508	proteolysis	The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.
	GO:0030193	regulation of blood coagulation	Any process that modulates the frequency, rate or extent of blood coagulation.
	GO:0008360	regulation of cell shape	Any process that modulates the surface configuration of a cell.
	GO:0051480	regulation of cytosolic calcium ion concentration	Any process involved in the maintenance of an internal steady state of calcium ions within the cytosol of a cell or between the cytosol and its surroundings.
	GO:0010468	regulation of gene expression	Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
	GO:0014854	response to inactivity	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inactivity stimulus.
	GO:0009611	response to wounding	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to the organism.
	GO:0006465	signal peptide processing	The proteolytic removal of a signal peptide from a protein during or after transport to a specific location in the cell.
cellular component
	GO:0005796	Golgi lumen	The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks.
	GO:0072562	blood microparticle	A phospholipid microvesicle that is derived from any of several cell types, such as platelets, blood cells, endothelial cells, or others, and contains membrane receptors as well as other proteins characteristic of the parental cell. Microparticles are heterogeneous in size, and are characterized as microvesicles free of nucleic acids.
	GO:0005788	endoplasmic reticulum lumen	The volume enclosed by the membranes of the endoplasmic reticulum.
	GO:0070062	extracellular exosome	A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm.
	GO:0031012	extracellular matrix	A structure lying external to one or more cells, which provides structural support for cells or tissues.
	GO:0005576	extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
	GO:0005615	extracellular space	That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Chain I (HIRV2_HIRME | P09945)

molecular function
	GO:0004857	enzyme inhibitor activity	Binds to and stops, prevents or reduces the activity of an enzyme.
	GO:0030414	peptidase inhibitor activity	Stops, prevents or reduces the activity of a peptidase, any enzyme that catalyzes the hydrolysis peptide bonds.
	GO:0004867	serine-type endopeptidase inhibitor activity	Stops, prevents or reduces the activity of serine-type endopeptidases, enzymes that catalyze the hydrolysis of nonterminal peptide bonds in a polypeptide chain; a serine residue (and a histidine residue) are at the active center of the enzyme.
biological process
	GO:0010951	negative regulation of endopeptidase activity	Any process that decreases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins.
	GO:0010466	negative regulation of peptidase activity	Any process that stops or reduces the rate of peptidase activity, the hydrolysis of peptide bonds within proteins.
cellular component
	GO:0005576	extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.

Visualization

Interactive Views

Still Images

Databases and Analysis Tools

Databases

Analysis Tools

Related Entries

Entries Sharing at Least One Protein Chain (UniProt ID)

Related Entries Specified in the PDB File

1a2c	STRUCTURE OF THROMBIN INHIBITED BY AERUGINOSIN298-A FROM A BLUE-GREEN ALGA
1a3b	COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1
1a3e	COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2
1a46	THROMBIN COMPLEXED WITH HIRUGEN AND A BETA- STRAND MIMETIC INHIBITOR
1a4w	CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE- CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE
1a5g	HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1a61	THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
1abi	ALPHA-THROMBIN COMPLEX WITH HIRULOG 3
1abj	ALPHA-THROMBIN COMPLEX WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE (PPACK) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1ad8	COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
1ae8	HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D- PHE-PRO-AZALYS-ONP
1afe	HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO- AZALYS-ONP
1aht	MOL_ID: 1; MOLECULE: ALPHA-THROMBIN; CHAIN: L, H; EC: 3.4.21.5; MOL_ID: 2; MOLECULE: HIRUGEN; CHAIN: I; HETEROGEN: P- AMIDINO-PHENYL-PYRUVATE
1ai8	HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA- PRO-BOROMPG
1aix	HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL
1awf	NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1awh	NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1ay6	THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF
1b5g	HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1b7x	STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D- PHE-PRO-ARG- CHLOROMETHYLKETONE
1ba8	THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES
1bb0	THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1bcu	ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN
1bhx	X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229- 357
1bmm	HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R, R)]-4- [(AMINOIMINOMETHYL)AMINO]-N-[[1-[3- HYDROXY-2-[(2- NAPHTHALENYLSULFONYL)AMINO]-1- OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)
1bmn	HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R, R)]-1- (AMINOIMINOMETHYL)-N-[[1-[N-[(2- NAPHTHALENYLSULFONYL)-L- SERYL]-PYRROLIDINYL] METHYL]-3-PIPERIDENECARBOXAMIDE (BMS- 189090)
1bth	STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1c1u	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1c1v	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1c1w	RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1c4u	SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1c4v	SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1c4y	SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS
1c5l	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1- BINDING, SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1c5n	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1- BINDING, SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1c5o	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1- BINDING, SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1ca8	THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1d3d	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4
1d3p	CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3
1d3q	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2
1d3t	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1
1d4p	CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5- AMIDINOINDOLE-4- BENZYLPIPERIDINE INHIBITOR
1d6w	STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON- ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1d9i	STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON- ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1de7	INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA- THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
1dit	COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN
1dm4	SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16)
1doj	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN* RWJ-51438 COMPLEXAT 1.7 A
1dwb	ALPHA-THROMBIN COMPLEX WITH (DES-AMINO ASP 55) HIRUDIN (RESIDUES 55 - 65) AND BENZAMIDINE
1dwc	ALPHA-THROMBIN COMPLEX WITH (DES-AMINO ASP 55) HIRUDIN (RESIDUES 55 - 65) AND MD-805 (ARGATROBAN)
1dwd	ALPHA-THROMBIN COMPLEX WITH (DES-AMINO ASP 55) HIRUDIN (RESIDUES 55 - 65) AND NAPAP
1dwe	ALPHA-THROMBIN COMPLEX WITH (DES-AMINO ASP 55) HIRUDIN (RESIDUES 55 - 65) AND D-PHE- PRO-ARG-CHLOROMETHYLKETONE (PPACK) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1dx5	CRYSTAL STRUCTURE OF THE THROMBIN- THROMBOMODULIN COMPLEX
1e0f	CRYSTAL STRUCTURE OF THE HUMAN ALPHA- THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II- BINDING INHIBITOR
1eb1	COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N- METHYL-ARGININE INHIBITOR
1eoj	DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1eol	DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1fpc	ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR DANSYLARGININE N-(3-ETHYL -1,5-PENTANEDIYL) AMIDE (DAPA)
1fph	ALPHA-THROMBIN TERNARY COMPLEX WITH HIRUDIN AND FIBRINOPEPTIDE A
1g30	THROMBIN INHIBITOR COMPLEX
1g32	THROMBIN INHIBITOR COMPLEX
1g37	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITHBCH -10556 AND EXOSITE-DIRECTED PEPTIDE
1ghv	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1ghw	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1ghx	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1ghy	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1gj4	SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA,SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1gj5	SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA,SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1h8d	X-RAY STRUCTURE OF THE HUMAN ALPHA- THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
1h8i	X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA- THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
1hag	PRETHROMBIN2 COMPLEXED WITH HIRUGEN (N- ACETYLHIRUDIN 53 - 64 WITH SULFATO-TYR 63)
1hah	ALPHA THROMBIN COMPLEXED WITH HIRUGEN (N- ACETYLHIRUDIN 53 - 64 WITH SULFATO-TYR 63)
1hai	ALPHA THROMBIN COMPLEXED WITH D-PHE-PRO- ARG- CHLOROMETHYLKETONE (PPACK) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1hao	COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DEOXYRIBONUCLEIC ACID)
1hap	COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DEOXYRIBONUCLEIC ACID)
1hbt	HUMAN ALPHA-THROMBIN COMPLEXED WITH A PEPTIDYL PYRIDINIUM METHYL KETONE CONTAINING BIVALENT INHIBITOR
1hdt	MOL_ID: 1; MOLECULE: ALPHA-THROMBIN; CHAIN: L, H; EC: 3.4.21.5; MOL_ID: 2; MOLECULE: HIRUGEN PEPTIDE; CHAIN: P; ENGINEERED: YES; MOL_ID: 3; MOLECULE: N-[N -[N-[4- (AMINOIMINOMETHYL)AMINO]-1-OXOBUTYL]- L -PHENYLALANYL]-L- ALLO-THREONYL-L- PHENYLALANINE, METHYL ESTER (BMS-183507); CHAIN: I; ENGINEERED: YES
1hgt	ALPHA-THROMBIN COMPLEX WITH HIRUGEN
1hlt	ALPHA THROMBIN COMPLEXED WITH THROMBOMODULIN (NONDECAPEPTIDE) AND D-PHE-PRO-ARG- CHLOROMETHYLKETONE (PPACK) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1hut	ALPHA-THROMBIN COMPLEXED WITH DEOXYRIBONUCLEIC ACID (5'- D(GPGPTPTPGPGPTPGPTPGPGPTPTPGPG)-3') AND D-PHE-PRO-ARG- CHLOROMETHYLKETONE (PPACK ) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1hxe	SERINE PROTEASE
1hxf	HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT
1ihs	ALPHA-THROMBIN COMPLEX WITH HIRUTONIN-2
1iht	ALPHA-THROMBIN COMPLEX WITH HIRUTONIN-6
1jmo	CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II -S195A THROMBINCOMPLEX
1jou	CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH ANUNOCCUPIED ACTIVE SITE
1jwt	CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVELBICYCLIC LACTAM INHIBITOR
1k21	HUMAN THROMBIN-INHIBITOR COMPLEX
1k22	HUMAN THROMBIN-INHIBITOR COMPLEX
1kts	THROMBIN INHIBITOR COMPLEX
1ktt	THROMBIN INHIBITOR COMPLEX
1lhc	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D) PHE-PRO-BOROARG- OH
1lhd	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D) PHE-PRO-BOROLYS- OH
1lhe	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D) PHE-PRO-BORO-N- BUTYL-AMIDINO-GLYCINE-OH
1lhf	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D) PHE-PRO-BORO- HOMOLYS-OH
1lhg	HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D) PHE-PRO- BOROORNITHINE-OH
1mh0	CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1mu6	CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378,622
1mu8	THROMBIN-HIRUGEN_L-378,650
1mue	THROMBIN-HIRUGEN-L405,426
1nm6	THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR AT1.8A
1no9	DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATINGNOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X- RAYCRYSTALLOGRAPHIC STUDIES.
1nrn	ALPHA-THROMBIN NON-COVALENTLY COMPLEXED WITH RECEPTOR BASED PEPTIDE NRS
1nro	ALPHA-THROMBIN NON-COVALENTLY COMPLEXED WITH RECEPTOR BASED PEPTIDE NRP
1nrp	ALPHA-THROMBIN NON-COVALENTLY COMPLEXED WITH RECEPTOR BASED PEPTIDE NR'S
1nrq	ALPHA-THROMBIN NON-COVALENTLY COMPLEXED WITH RECEPTOR BASED PEPTIDE D-FPR'S
1nrr	ALPHA-THROMBIN NON-COVALENTLY COMPLEXED WITH RECEPTOR BASED PEPTIDE XA AND D-PHE-PRO- ARG CHLOROMETHYLKETONE (PPACK) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1nrs	ALPHA-THROMBIN NON-COVALENTLY COMPLEXED WITH RECEPTOR BASED PEPTIDE NRP (CLEAVED, FIRST FOUR RESIDUES ONLY) AND HIRUGEN
1nt1	THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR
1nu7	STAPHYLOCOAGULASE-THROMBIN COMPLEX
1nu9	STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX
1ny2	HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN
1nzq	D-PHE-PRO-ARG-TYPE THROMBIN INHIBITOR
1o0d	HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO -ARG- TYPEINHIBITOR AND A C-TERMINAL HIRUDIN DERIVED EXO- SITEINHIBITOR
1o2g	ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATINGBINDING OF ACTIVE SITE- DIRECTED SERINE PROTEASE INHIBITORS
1ook	CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB- ALPHA AND HUMAN ALPHA- THROMBIN
1oyt	COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNEDFLUORINATED INHIBITOR
1p8v	CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB- ALPHA AND ALPHA-THROMBIN AT 2.6A
1ppb	ALPHA-THROMBIN COMPLEX WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE (PPACK) WITH CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP
1qbv	CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE- MIMETIC INHIBITOR
1qhr	NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1qj1	NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1qj6	NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1qj7	NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1qur	HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE- BASED SYNTHETIC INHIBITOR
1qvh	CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THECENTRAL "E" REGION OF FIBRIN
1rd3	2.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1sb1	NOVEL NON-COVALENT THROMBIN INHIBITORS INCORPORATING P1 4, 5,6,7- TETRAHYDROBENZOTHIAZOLE ARGININE SIDE CHAIN MIMETICS
1sfq	FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
1sg8	CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
1sgi	CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1shh	SLOW FORM OF THROMBIN BOUND WITH PPACK
1sl3	CRYSTAL STRUCTUE OF THROMBIN IN COMPLEX WITH A POTENT P1HETEROCYCLE-ARYL BASED INHIBITOR
1sr5	ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEXSTRUCTURE
1ta2	CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 1
1ta6	CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 14B
1tb6	2.5A CRYSTAL STRUCTURE OF THE ANTITHROMBIN- THROMBIN- HEPARINTERNARY COMPLEX
1tbz	HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N- [5-(AMINOIMINOMETHYL)AMINO]- 1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L- PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
1thp	STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D- PHE-PRO-ARG- CHLOROMETHYLKETONE
1thr	ALPHA-THROMBIN COMPLEX WITH HIRULLIN
1ths	ALPHA-THROMBIN COMPLEX WITH MDL-28050
1tmb	ALPHA-THROMBIN COMPLEX WITH HIRUGEN AND CYCLOTHEONAMIDE A
1tmt	ALPHA-THROMBIN COMPLEXED WITH CGP 50,856 (D-PHE-PRO-ARG-PRO -GLY-GLY-GLY-GLY FOLLOWED BY RESIDUES 53 - 65 OF HIRUDIN, CLEAVED AFTER ARG I 3)
1tmu	ALPHA-THROMBIN TERNARY COMPLEX WITH HIRUDIN (C-TERMINAL FRAGMENT, RESIDUES 55 - 65) AND PPACK (D-PHE-PRO-ARG- CHLOROMETHYLKETONE)
1tom	ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1tq0	CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBINMUTANT W215A/E217A IN FREE FORM
1tq7	CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANTW215A/E217A BOUND TO PPACK
1uma	ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N- DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE
1uvs	BOVINE THROMBIN--BM51.1011 COMPLEX
1vr1	SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR- 1
1vzq	COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165
2hgt	ALPHA-THROMBIN COMPLEX WITH HIRULOG I (CLEAVED BETWEEN ARG 3 AND PRO 4)
2hnt	GAMMA-THROMBIN
2hpp	ALPHA-THROMBIN COMPLEX WITH D-PHE-PRO-ARG - CHLOROMETHYLKETONE (PPACK) CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP AND BOVINE PROTHROMBIN FRAGMENT 2
2hpq	ALPHA-THROMBIN COMPLEX WITH D-PHE-PRO-ARG - CHLOROMETHYLKETONE (PPACK) CHLOROMETHYLKETONE REPLACED BY A METHYLENE GROUP AND HUMAN PROTHROMBIN FRAGMENT 2
2thf	STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D- PHE-PRO-ARG- CHLOROMETHYLKETONE
3hat	ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND FPAM (FIBRINOPEPTIDE A MIMIC)
3htc	ALPHA-THROMBIN COMPLEX WITH RECOMBINANT HIRUDIN (VARIANT 2, LYS 47)
4htc	ALPHA-THROMBIN COMPLEX WITH RECOMBINANT HIRUDIN (VARIANT 2, LYS 47)
4thn	THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN- HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.
5gds	HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: HIRUNORM V COMPLEX
7kme	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.
8kme	CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.

Description

Compounds

Structural Features

Chains, Units

Ligands, Modified Residues, Ions (1, 1)

Sites (2, 2)

SS Bonds (4, 4)

Cis Peptide Bonds (1, 1)

Sequence-Structure Mapping

SAPs(SNPs)/Variants (8, 8)

PROSITE Motifs (3, 3)

Exons (7, 8)

Sequences/Alignments